stock markets for traders. period
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$TROV .96 nHOD > new 52W high
re-read 10Q again - all numbers are in "thousands"
operating income $7.2M
$TROV testin' 52W high
going up...
looks like she is going to break a buck this time...
Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine PR Newswire "Press Releases US - English"
SAN DIEGO , May 2, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV) announced today that the Company has initiated development of a diagnostic test to determine the presence of high risk Human Papilloma Virus (HPV) subtypes from urine specimens. The proprietary test (U.S. patent application pending) might, once available, be particularly useful for the determination of carrier status in males.
The Company's HPV detection assay is a unique, proprietary(1) method that preferentially amplifies a specific region of the HPV genome of high risk HPV types, but not of low risk types. In an explorative validation study the Company has compared the analytical performance of its assay, which uses urine as the sample, to a commercially available HPV test, which uses cytology samples and was performed according to the manufacturer's protocol. Discordant results were resolved by Sanger DNA sequencing. The results showed that the Trovagene assay performed with a sensitivity of 93% and a specificity of 96%, whereas the commercially available LBC test had a sensitivity of 78% and a specificity of 86%.
Trovagene 's HPV assay is compatible with the throughput and reliability requirements of a clinical-diagnostic laboratory at very competitive cost levels. The Company believes that the detection of high risk HPV types through its urine-based assay could have valuable clinical utility for monitoring the high risk HPV carrier status of an individual. Such infections can lead to cervical cancer, head-and neck cancer(2), and other cancers.
Charlie Rodi , Ph.D., Trovagene 's Chief Technology Officer, stated that "the Company's HPV assay technology is noteworthy for both its high performance and its ease of use. The urine sample can be collected in private and shipped at ambient temperatures to a diagnostic laboratory." He also noted that although there is no HPV test currently recommended for use by men, that the Company's urine-based test has the potential to determine male carrier status without resorting to methods that require scraping to collect cytology samples. Dr. Rodi added that the Company plans to begin offering the test in 2012.
1. WO2010051261, IPA No. PCT/US2009/062114, Indian Patent Application No. 3673/DELNP/2011
2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States (2011) Journal of Clinical Oncology 29(32): 4294-4301.
ok, thanks
I know 'bout them... my question was about TROV's info that you got from goodetrades guy... Did I misread something?
about this:
care to share?
$NEXS: should be over a buck...
CHARLOTTE, N.C., May 1, 2012 /PRNewswire/ -- Nexxus Lighting, Inc. (NEXS) today announced that it is exploring strategic alternatives available to the company, including a possible sale. The Board of Directors intends to consider the full range of available options. The company also announced that it has engaged Canaccord Genuity to assist in the evaluation of these options.
biomedreports didn't help last time... good luck anyways...
hey, can you post the whole email? I subscribed to PSH but never got this alert...
SMA email:
For those who missed out or waited on the sidelines, now is your chance!
SEFE preliminary report was delivered to your inbox last week. The stock reacted very favorably, nearly doubling in just a few trading session. The stock has since pulled back and created entry for those sitting on the sidelines waiting to buy.
SMA investors remember that our feature pick last year took 25 days to deliver 968% gains. Stock Market Authority wishes to reassure members that we have only just initiated coverage on SEFE and strongly feel that the best is yet to come!
Our feature pick from last year also experienced heavy shorting and profit-taking which led to a precipitous pullback in the early stages. The faithful investor who refused to be shaken out was rewarded with a phenomenal return - a gain which no other newsletter on the planet can duplicate. We have set the bar with our previous Stock Pick of the Year, and fully expect SEFE to follow a similar path.
Which side of the fence do you sit on? Will you let short sellers and panic selling rob you of your hard earned profits? Or do you have faith in the merits of an amazing technology company who's story is just being announced, and a newsletter which delivers winner after winner?
SEFE is consolidating and getting ready to bounce as you sit here and read this. This technology is too amazing and this story too compelling for SEFE to stay at such cheap levels much longer. As this story circulates, and SEFE continues to grow, do not hesitate, as you may later regret this. The time to act is now...
As we mentioned in our Stock Pick of the Year alert last week, SEFE still holds promise as the first major energy breakthrough of the 21st Century...with a stock price that could rise accordingly. Analysts' short term targets of $5.95 and medium term targets of $12.78 are still within range.
For more information about SEFE and their innovative technology, click here.
Call your broker or log into your online trading account and take advantage of a life-changing opportunity — today! And as a favor, please forward this to anyone who might be interested in seeing massive returns on their investment.
email from a few min back:
SEFE, Inc. (SEFE.OB) roller coaster has continued into today and panic selling has resumed. Illegal shorts have created tremendous downward pressure on the stock, and some weak hands have exited SEFE. This is unfortunate as the selling pressure appears to be letting up. When a short is executed, the sell is only one half of the equation. As these short sellers cover, they need to buy back stock which was previous sold. This translates to millions of shares which will need to be bought back. When this happens, the stock will stabilize and the uptrend will resume. Shorts only prosper when you sell your shares to them, and they can buy them back cheaper. Once the panic selling stops, they will have to buy back at the offers and this creates a natural lift in the stock.
From a corporate standpoint, SEFE continues to outperform. Nothing has changed and the company is growing. This technology is too amazing and this story too compelling for SEFE to sit here at these low levels without being bought up. As this promise of a brand new, cost effective, alternative energy circulates, and SEFE continues to grow, this pullback will prove to be a huge opportunity for those who may have missed our original alert SEFE is a major energy breakthrough, and has received short term targets of $5.95 and medium term targets of $12.78
To read the news in its entirety, or review public filings, charts, and historical quotes for SEFE, click here.
Have a friend who might be interested? Please forward this email and encourage them to sign up for our free newsletter at StocksDigest.com
Signed,
Chief Editor
Stocks Digest
you nailed it... i got in a few cents below
1.65 is the resistance
$KERX > up-trend confirmation
$KERX bouncing after weekly downtrend
only $5.1M Market Cap as of today...
http://www.prnewswire.com/news-releases/rainchief-acquires-90-interest-in-gulf-jensen-prospect-148081055.html
RainChief Acquires 90% Interest in Gulf Jensen Prospect
Commits to joint development with Nueva Oil & Gas
VANCOUVER, April 19, 2012 /PRNewswire/ - RainChief Energy Inc. [OTCBB: RCFEF] today announced that the company has exercised its option with Nueva Oil & Gas Corporation to acquire a 90% working interest in the Gulf Jensen Prospect, an oil property located in New Mexico's Permian Basin. Under the terms of the option and in accordance with the farmout agreement between the parties dated February 10, 2012, RainChief has paid a total of $110,000 to Nueve Oil & Gas in connection with the option exercise.
The Permian Basin has produced over 20 billion barrels of oil with a financial value that exceeds $2 trillion, based on today's oil prices. The Basin produces 17% of total United States crude oil and represents 66% of Texas' current oil production. Proven reserves are second only to Alaska and New Mexico's portion of the Basin holds three of the 100 largest oil fields in the US.
Calgary-based Nueva Oil & Gas will retain a 10% working interest in the Gulf Jensen property and will manage all exploration and development activities on the Gulf Jensen property. Nueva is controlled by Norman Mackenzie, who is also the founder of C&C Energia [TSX: CZE]. Mr. Mackenzie will directly advise RainChief on all aspects of site geology and project development.
In exercising the option, RainChief CEO Paul Heney stated, "This is an important move for RainChief. We're partnering with Nueva and Norman Mackenzie in what we believe is a very high quality oil property. An extensive engineering review of the open-hole electric logs from the original #1 Jensen strongly supports our plan to drill new offset oil wells. Analysis of the property and comparison with other similar geological structures and hydrocarbon production within this region of the Permian Basin supports our belief that the Gulf Jensen Prospect has very positive development potential."
The Gulf Jensen Prospect includes 2,400 gross acres of oil and gas leases and is located in the New Mexico portion of the Permian Basin, an area covering portions of west-central Texas and southeast New Mexico. In the New Mexico region of the Basin there are currently 52,560 producing oil and gas wells and 65 active rigs in operation.
The neighboring Peterson oil field has recorded well production rates to 492 barrels of oil a day with 193 barrels of formation water from the reef oil trap. Per well oil recoveries range up to 230,000 barrels of oil with 1 billion cubic feet of natural gas. Analysis of the Prospect and comparison with the Peterson oil field indicates that the Gulf Jensen Prospect could contain significant levels of oil and natural gas equivalent.
RainChief Energy is actively engaged in identifying, financing & developing oil & gas energy resource properties in North America, including the development of the Gulf Jensen Oil Prospect in New Mexico. The company continues to review additional resource properties that combine positive elements of short-term exploration & development costs with high potential for long-term success & financial return.
Rainchief Energy currently has the following share capitalization as of April 19, 2012:
Issued and Outstanding: 36,867,241
Warrants: 4,885,000
Fully Diluted: 41,752,242
Held in DTCC: 12,050,515
Additional information can be found at: www.rainchief.com
Nueva Oil & Gas is headed by well-know Canadian oilman, Norman Mackenzie, who is also Founder and Director of C&C Energia. C&C is a publicly traded, independent oil and gas company that trades on the Toronto Stock Exchange [TSX: CZE]. The company's operations are in Colombia, South America with offices in Bogota, Colombia and Calgary. C&C currently operates 100% of its oil production and holds interests in eight blocks in Colombia totaling 647,500 acres [559,000 net acres].
Additional information can be found at: www.ccenergialtd.com
On behalf of the Board of Directors,
RainChief Energy Inc. (OTCBB: RCFEF)
"Brad J. Moynes"
Brad J. Moynes
President
$EBIG: EastBridge Investment Group's Client, Wonder, Reports 2011 Performance
PHOENIX, AZ--(Marketwire -04/17/12)- EastBridge Investment Group (OTC.BB: EBIG.OB) (OTCQB: EBIG.OB) announced today its client, Wonder International Education and Investment Group International, has reported their 2011 financial results. The December 31, 2011 revenue was $14,839,050 compared to $12,714,429 for December 31, 2010. The December 31, 2011 comprehensive income was $7,148,689 compared to $6,386,508 for December 31, 2010.
Norm Klein, CFO/COO of EastBridge, commented, "We are very pleased with Wonder's performance. As we are getting closer to Wonder's stock beginning to trade, we are encouraged by their management's continued push into new areas of revenue and on their generic growth. The plan for Wonder is to become listed on the OTCBB first, then move up to the Nasdaq as soon as permissible by Nasdaq, according to their new policy."
EastBridge Investment Group focuses on high-growth companies in Asia, offering IPOs, Joint Ventures and Merchant Banking services. The Company targets industries in the education, internet, energy, mining and service sectors. To learn more about EastBridge Investment Group go to our web site: www.EbigCorp.com. To receive EBIG's email alert, send a blank email to info@EbigCorp.com. Join us on Facebook at the following link: http://www.facebook.com/ebigcorp.
$EBIG > hearing that this crap is going to be promoted
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8538556
Total other expense (income) (4,185,049)
Loss from operations (1,846,183)
4,185,049 - 1,846,183 = 2,338,866 this is the net gain
one time gain (not on accounts (cash) yet because it's from the settlement (???) and still under receivables) made these ridiculous numbers.
Hope this helps
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8193931
The closing of the acquisition of the Assets was subject to the satisfaction by the parties of certain obligations, including, among other things, the transfer of title to the Company of the Owned Claims, the assignment of Seller’s leasehold interests to the Company and the payment of consideration by the Company for the Assets (the “Closing Conditions”). On April 5, 2012, the parties satisfied the Closing Conditions and the Company issued to VGC 10,000,000 shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), and a 2 year warrant (the “Warrant”) to purchase 5,000,000 shares of Common Stock at a purchase price of $0.60 per share. The Company also granted a 2% net smelter returns royalty on production from the Owned Claims which are not encumbered by production royalties payable to Newmont under the 2006 Mineral Lease. The Company also paid the Seller $2,000,000 cash.
$MSHL > big volume... this pos had the S-1 a month back...
Marshall Edwards Receives FDA Approval of Investigational New Drug Application for Clinical Testing of Oncology Drug Candidate ME-344
SAN DIEGO, April 10, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has received approval from the U.S Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for ME-344, the Company's lead mitochondrial inhibitor. The Company is now in the process of initiating a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors.
"With this important milestone, we have now successfully advanced our two most promising oncology drug candidates into the clinic," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "As we near the completion of our Phase I clinical trial of ME-143 and prepare for its next phase of development, we are excited to initiate our first human study of ME-344. We believe ME-344 is a novel compound that has the potential to significantly improve treatment outcomes for patients with cancer, but first it is important to confirm its safety and tolerability in patients while establishing an optimal dose for future trials."
The Phase I clinical trial of ME-344 is being conducted in collaboration with the Sarah Cannon Research Institute. The open-label, dose-escalation trial will evaluate the safety and tolerability of intravenous ME-344 in patients with refractory solid tumors. In addition, the trial is designed to characterize its pharmacokinetic profile and describe any preliminary clinical anti-tumor activity observed. Patients will be administered intravenous infusions of ME-344 once weekly for three weeks and, after safety assessment, may continue weekly dosing if a clinical benefit is determined. The trial is expected to enroll up to 24 patients at three sites. Additional information regarding the trial, including enrollment criteria and site information, is available on the U.S. National Institutes of Health (NIH) clinical trials database at www.clinicaltrials.gov.
About ME-344
ME-344 is the Company's lead mitochondrial inhibitor and an active metabolite of NV-128, a first-generation compound. In April 2011, Ayesha Alvero, M.D., Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine, presented data at the American Association for Cancer Research Annual Meeting from a pre-clinical study of NV-128 demonstrating its ability to induce mitochondrial instability, ultimately leading to cell death in otherwise chemotherapy-resistant ovarian cancer stem cells. These results were later published in the August 2011 issue of Molecular Cancer Therapeutics. In additional pre-clinical studies, ME-344 has demonstrated far superior anti-tumor activity against a broad range of human cancer cell lines compared to NV-128, including breast, colorectal and ovarian. Marshall Edwards owns exclusive worldwide rights to all of its drug candidates, including ME-344.
About Marshall Edwards
Marshall Edwards, Inc. (Nasdaq: MSH) is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company's lead drug candidates, ME-143 and ME-344, have been shown in laboratory studies to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. Marshall Edwards initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors in September 2011 and plans to present safety and pharmacokinetic data from the trial at the American Society of Clinical Oncology Annual Meeting in June 2012. The Company received approval of its Investigational New Drug application for ME-344 in April 2012 and is in the process of initiating a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors. For more information, please visit www.marshalledwardsinc.com.
snpk > probably the last day of promo...
VALV > half of float has been traded
SEFE, PGLC & SNPK > who'll be at $2 first? lol
perfect trading strategy
k, looks I missed those...
$EMPM > first day of $750K promo; play it right...
news:
Empire Post Media Takes Worldwide Distribution of 'Journey Beyond' Television Series In House After Addition of Reality TV Showrunner Stuart Schwartz to Production Team
LOS ANGELES, March 26, 2012 (GLOBE NEWSWIRE) -- Empire Post Media Inc. (OTCQB:EMPM.PK) has decided to take, in house, the distribution chores previously contracted to The Fremantle Corporation with the addition of six-time Emmy nominee Stuart Schwartz to the production team of "Journey Beyond" as executive producer and showrunner.
Empire CEO Peter Dunn stated, "The addition of Stuart to the team, along with his great pedigree and connections in the television business, provides an opportunity to manage the distribution of our products in-house, thus eliminating third-party sales costs and commissions thereby increasing bottom line revenues to the company.
"Due to the global popularity of the 'Journey Beyond' genre, projected revenues, assuming a five year run, and based on current market data, are estimated at $35,000,000, with each episode in the first season expected to generate approximately $260,000, and growing to over $400,000 per episode in the fifth year, not including revenue from the 3D version, which could be substantial," Dunn added.
Empire has previously announced a $1,500,000 finance facility, in place, to produce the show.
Schwartz, a former top executive with Cosgrove/Meurer, has produced 174 episodes of perennial TV hit "Unsolved Mysteries."
"Journey Beyond," which was created by Ellen Fontana and Richard Mann, principals of Empire's wholly owned subsidiary Hybrid-Reality Entertainment, deals with paranormal and psychic events, based on the real stories of real people. The show is being produced in 3D for delivery in 2D HD and 3D.
Further information about Empire Post Media can be obtained from the company's web site, www.empirepostmedia.com.
www.hybridrealityentertainment.com.
EMPM > 1st day of $750K promo
clgl > they're selling more that I could buy... took a haircut...
California Gold Corp.: Agreement with American Strategic Minerals Corporation
LA CANADA , Calif., March 26, 2012 /CNW/ - California Gold Corp. (OTC BB: CLGL) ("California Gold" or, the "Company") announced today that it entered into an agreement with American Strategic Minerals Corporation ("Amicor"). As set forth in the agreement, Amicor will provide the Company with a geological review (the "Report") of Amicor's Bull Canyon and Martin Mesa properties in Montrose County, Colorado, pursuant to which California Gold may determine and identify the approximate locations and scope of geologic formations that could contain potential gold deposits on these properties. Amicor will deliver the report on or prior to March 30, 2012 .
In consideration for delivery of the Report, the Company agreed to pay Amicor $125,000 , which payment may, at the election of the Company, be paid in cash or in unregistered shares of the Company's common stock. In the event that the Company elects to pay Amicor in shares of common stock, it shall deliver such number of shares of common stock that shall be equal to the number which results from dividing $125,000 by the closing price of a share of common stock as quoted on the Over the Counter Bulletin Board on March 19, 2012 .
For more information on the Company and its projects, go to the California Gold website: www.californiagoldcorp.com.
California Gold Corp.: Agreement with American Strategic Minerals Corporation
LA CANADA , Calif., March 26, 2012 /CNW/ - California Gold Corp. (OTC BB: CLGL) ("California Gold" or, the "Company") announced today that it entered into an agreement with American Strategic Minerals Corporation ("Amicor"). As set forth in the agreement, Amicor will provide the Company with a geological review (the "Report") of Amicor's Bull Canyon and Martin Mesa properties in Montrose County, Colorado, pursuant to which California Gold may determine and identify the approximate locations and scope of geologic formations that could contain potential gold deposits on these properties. Amicor will deliver the report on or prior to March 30, 2012 .
In consideration for delivery of the Report, the Company agreed to pay Amicor $125,000 , which payment may, at the election of the Company, be paid in cash or in unregistered shares of the Company's common stock. In the event that the Company elects to pay Amicor in shares of common stock, it shall deliver such number of shares of common stock that shall be equal to the number which results from dividing $125,000 by the closing price of a share of common stock as quoted on the Over the Counter Bulletin Board on March 19, 2012 .
For more information on the Company and its projects, go to the California Gold website: www.californiagoldcorp.com.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8503599
On March 19, 2012, California Gold Corp. (“we” or, the “Company”) entered into an agreement with American Strategic Minerals Corporation, a Nevada corporation (“Amicor”), pursuant to which for the consideration of $125,000, we will receive a report (the “Report”) from Amicor concerning the geological formations on two properties (the “Amicor Properties”) in Bull Canyon and Martin Mesa, Montrose County, Colorado. Amicor owns mining leases covering unpatented mining claims on the Amicor Properties. We will review the Report to determine and identify the approximate locations and scope of geological formations, if any, that could contain potential gold deposits.